glp 1 and cancer risk Forest plot of GLP-1 receptor agonists versus comparators on of GLP-1 drugs cut breast cancer
Description
N Engl J Med 375:311322 Ahrn B, Masmiquel L, Kumar H, Sargin M, Karsbl JD, Jacobsen SH, Chow F (2017) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Beyond the pancreas, the GIP receptor (GIPR) is expressed within the pericytes and mesothelial cells of the adipose tissue (Campbell et al
Regardless of their characteristics, it might be reasonable to employ long-acting, sustained release formulations to maintain optimal steady-state therapeutic drug levels in light of difficulties in cognitive and motor function of patients with PD and other neurodegenerative diseases to best achieve compliance and efficacy
doi: 10.1161/atv.0000615456.97862.30 52 BanKNoyan-AshrafMHHoeferJBolzSSDruckerDJHusainM
Compounded tirzepatide is made in the U.S
It helps control hunger, balance blood sugar, and promote sustainable fat loss
